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Iso et al., 2001). A closely related concept (WilliamsonSorbitol dehydrogenase (hSDH) and aldose reductase
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2002) emphasizes the importance of the increase in theand fructose. Redox changes from overproduction of
the coenzyme NADH by SDH may play a role in diabe- cytoplasmic free NADH/NAD ratio that results from ex-
cessive oxidation of sorbitol to fructose by SDH, creat-tes-induced dysfunction in sensitive tissues, making
SDH a therapeutic target for diabetic complications. ing a “pseudo-hypoxic” state that contributes to glu-
cose-linked oxidative stress (Williamson et al., 1993;We have purified and determined the crystal structures
of human SDH alone, SDH with NAD, and SDH with Tilton, 2002) and is therefore a central determinant of
vascular dysfunction and eventual pathology in diabeticNADH and an inhibitor that is competitive with fruc-
tose. hSDH is a tetramer of identical, catalytically ac- tissues (Rosen et al., 2001). Specific inhibitors of SDH
are needed to study the role of excess flux through SDHtive subunits. In the apo and NAD complex, the cata-
lytic zinc is coordinated by His69, Cys44, Glu70, and in the development of diabetic complications.
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activity by directly chelating the catalytic zinc (Mylarimore potent inhibitors of hSDH.
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available. Recently, two X-ray crystal structures have
contributed to our knowledge of the SDH enzymes. TheDiabetes mellitus afflicts approximately 151 million peo-
3.0 A˚ resolution structure of rat sorbitol dehydrogenaseple worldwide, with an estimated increase to 221 million
has been determined (Johansson et al., 2001), as hasby 2010 (Zimmet et al., 2001). Diabetic individuals often
a high-resolution structure of the silverleaf whiteflysuffer debilitating long-term complications such as
NADP(H)-dependent ketose reductase (Banfield et al.,
2001), which preferentially catalyzes the reduction of*Correspondence: virginiar@thiospharm.com
5 Current address: Pfizer Global Research and Development, La Jolla fructose to sorbitol. Crystals of human SDH have also
Laboratories, 3665 General Atomics Court, San Diego, California 92121. been reported (Darmanin et al., 2003).
6 Current address: Department of Biochemistry and Molecular Biol- Here, we present the first X-ray crystal structures of
ogy, Michigan State University, East Lansing, Michigan 48824. human sorbitol dehydrogenase (hSDH, E.C. 1.1.1.14),7 Current address: Pfizer Discovery Technology Center, 620 Memo-
as well as hSDH plus its required cofactor, NAD, andrial Drive, Cambridge, Massachusetts 02139.
a ternary complex of hSDH, NADH, and a reversible8 Current address: Thios Pharmaceuticals, Inc., 5980 Horton Street,
Suite 400, Emeryville, California 94608. active site inhibitor, CP-166,572. These X-ray structures
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Figure 1. Substrates, Cofactors, and Inhibi-
tors of hSDH
(A) The polyol pathway consists of two en-
zymes: aldose reductase (AR) and sorbitol
dehydrogenase (SDH). The structures of sor-
bitol and fructose are shown with their re-
spective carbon atoms numbered. The nico-
tinamide ring of NAD and NADH are shown,
R represents the adenine dinucleotide por-
tion of both molecules (omitted for simplicity).
(B) Prodrug SDI-157 and CP-166,572 ( SDI-
158 [7], WAY-135706 [32]). Structures and in-
hibition constants (IC50) for each molecule are
shown. Figures made in ChemDraw (Cam-
bridgeSoft, 2001).
provide experimental evidence that, when combined fructose but binds with greater affinity due to improved
hydrophobic contacts.with kinetic, ligand binding, and literature data, allow us
to delineate each step along the SDH reaction pathway
(Figure 1A). The structure of native SDH corresponds to Results and Discussion
the “ground state” of the enzyme and reveals the ligands
to the catalytic zinc in the absence of cofactor or sub- Complexes Solved
We first crystallized the human enzyme as a complexstrate. The structure of SDH complexed with NAD re-
veals the surprisingly slight structural changes the pro- with NADH and inhibitor CP-166,572 with four molecules
in the asymmetric unit (Table 1). The structure wastein makes when binding the cofactor in the first step
of the ordered reaction. The third structure, a complex solved by the method of single anomalous diffraction
(SAD) with phase information derived from the anoma-of SDH/NADH and the inhibitor CP-166,572, together
with our kinetic studies showing that CP-166,572 is a lous scattering of 32 selenium atoms from four mole-
cules of selenomethionine-substituted hSDH (Table 1).competitive inhibitor with respect to fructose (but not
with respect to sorbitol, NAD, or NADH), allows us to Subsequently, we crystallized the enzyme alone and as
a complex with NAD (Table 1).propose a molecular model for (1) the binding of fructose
(and sorbitol) in their linear forms, and (2) inhibition by All three complexes (native SDH, SDH/NAD, and
SDH/NADH/CP-166,572) crystallized in the same spaceCP-166,572, whose binding site overlaps with linear
Structure of Human Sorbitol Dehydrogenase
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Table 1. Crystallographic Data and Refinement Statistics
Crystal Native NAD SeSDH/NADH/CP-166,572
Space group P62 P62 P62
Cell dimensions (A˚)
a  b  134.95 133.78 135.05
c  224.69 224.71 225.49
Data Collection Statistics
Wavelength (A˚) 0.979 1.0 0.97949 (peak)
Resolution (A˚) 99.0–2.1 99.0–1.9 99.0–1.9
Unique Reflections 125,211 161,025 178,211
Redundancy 4 4 9
Chi2 1.15 (1.02) 1.0 (0.91) 1.43 (0.96)
Rmerge 0.122 (0.527) 0.083 (0.379) 0.124 (0.581)
I/error 11.6 (2.0) 12.8 (2.0) 33.6 (1.8)
Completeness 0.922 (0.604) 0.886 (0.442) 0.996 (0.883)
Phasing Statistics
Phasing power (friedels) 1.24
FOM (overall) 0.27
Rcullis 0.73
Mean FOM (after solvent flipping [CNS]) 0.99
Solvent content 0.65
Refinement Statistics
Resolution (A˚) 43.2–2.2 45.8–1.9 57.8–2.0
R 0.200 (0.254) 0.195 (0.270) 0.183 (0.244)
Rfree 0.233 (0.279) 0.222 (0.291) 0.211 (0.221)
Rmsd bond lengths (A˚) 0.006 0.005 0.008
Rmsd bond angles () 1.3 1.4 1.5
Protein 1–356 1–356 1–356
Ligands 4 Zn 4 Zn/4 NAD 4 Zn/4 NADH/4 CP-166,572
Resolution, chi2, Rmerge, I/error (Intensity divided by error), and completeness values taken from Scalepack results (Otwinowski and Minor,
1997). Rmerge  hi|I(h)  Ii(h) |/hiIi(h) where Ii(h) and I(h) are the ith and the mean measurement of the intensity of reflection h. Rcryst 
h [|Fobs(h)  Fcal(h)|/hFobs(h)] where Fobs(h) and Fcal(h) are the observed and calculated structure factor amplitudes. Rfree is computed
using 10% of the reflections from each resolution shell, randomly selected.
group, P62, with similar cell dimensions. Comparing the accessible surface in the native structure, more than
refined coordinates shows that the three structures are twice the interface area formed by subunits A and B
very similar, with a root-mean-square deviation for all within the tetramer (1233 A˚2). In forming the tetramer,
C atoms of 0.2 to 0.3 A˚ for superposition of SDH/NAD the AD dimer contacts the BC dimer at two regions,
and SDH/NADH/CP-166,572 onto native SDH. Com- sequestering a total of 7510 A˚2 of solvent-accessible
pared to SDH alone, the relative orientations of the sub- surface per dimer.
units and the domains are not significantly altered on The N-terminal seven residues of the protein provide
binding NAD or both NADH/CP-166,572. We compared a striking crystal contact (Figure 2B). These residues
the area buried between the subunits and between the pack between two  strands of a crystallographic sym-
two domains of each complex and found negligible metry mate (strand residues 321–328 and 352–356 of
changes of 100–200 A˚2. Some differences between the subunit B), forming a link between the two B subunits
three structures are expected because freezing the crys- from different tetramers. In solution, residues 1–7 are
tals results in unit cell changes, even for similar-sized expected to pack against  strands from their own sub-
crystals grown under identical conditions. unit (residues 24–31 and 72–79). This alternate confor-
mation of the N terminus may be required to stabilize
the lattice, which has a solvent content of 65%.Overall Description of the Enzyme
The overall fold of one subunit of hSDH is similar toSDH is a tetramer (Jeffrey et al., 1981; Banfield et al.,
that of rat SDH (coordinates not available), as expected,2001; Johansson et al., 2001), with each subunit con-
but is also closely related to the folds of NADPH-depen-sisting of 356 residues (38 kDa) and one catalytic zinc
dent whitefly ketose reductase (rmsd of 1.3 A˚ for 345 Catom (Jeffrey et al., 1984; Maret, 1996). The four subunits
carbons) and horse liver alcohol dehydrogenase (ADH,are related by crystallographic and noncrystallographic
rmsd of 1.8 A˚ for 301 C carbons; 8ADH.pdb). The hSDHsymmetry and can be considered identical within the
monomer consists of two  barrel domains with a deepresolution of the data (see Experimental Procedures).
cleft between them (Figure 2B). The active site is locatedThe hSDH tetramer can be considered (like other me-
at the bottom of the cleft facing the surface of the tetra-dium-chain dehydrogenase/reductase family members;
mer. The coenzyme binding domain (residues 158–298)Ruzheinikov et al., 2001) as a dimer of identical dimers
is a classic Rossmann fold (Rossmann et al., 1974) that(dimer AD and dimer BC, Figure 2A). The largest dimer
reversibly binds the required NAD(H). The coenzymeinterface is formed between the A and D (or equivalent
B and C) subunits, burying a total of 2850 A˚2 of solvent- binds identically and with full occupancy in all subunits
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Figure 2. Overall View of hSDH
(A) Biological tetramer of human sorbitol dehydrogenase. A ribbon diagram of the tetramer coordinates derived from complex of hSDH with
zinc, NADH, and CP-166,572, which are shown as stick figures. Subunit A is colored green, B is blue, C is yellow, and D is red. All figures
prepared using Ribbons (Carson, 1991) with atoms colored as follows: zinc, purple; carbon, green; nitrogen, blue; oxygen, red; sulfur, yellow;
and water molecules, red spheres.
(B) Structure of the monomer of human sorbitol dehydrogenase. Ribbon diagram showing the overall fold of one subunit of human sorbitol
dehydrogenase and the location of CP-166,572, NADH, and the catalytic zinc atom.
of the tetramer. The larger catalytic domain (residues Stoichiometry and Michaelis Constants
of hSDH Ligands1–157, 299–356) houses the single zinc atom required
for activity. hSDH does not contain a second structural Human SDH catalyzes the reversible oxidation of the
C2 carbon of sorbitol to fructose with reduction of NADzinc atom like alcohol dehydrogenase (Eklund et al.,
1976) or the whitefly NADP(H) ketose reductase (Ban- to NADH (the “forward” direction, left to right in Figure
1A). SDH also readily catalyzes the reduction of fructosefield et al., 2001).
Structure of Human Sorbitol Dehydrogenase
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Figure 3. Functional and Structural Conse-
quences of Ligand Binding to hSDH
(A) Stoichiometry and codependence of li-
gand binding to hSDH. n  3, details as de-
scribed in Experimental Procedures.
(B) Zn ligands in hSDH (native). Stereo image
showing residues coordinating the catalytic
zinc (dashed lines) in hSDH in the absence
of NAD(H) or other ligands.
(C) Changes in hSDH on binding NAD. Ster-
eoview of superposition of C carbons of
hSDH native (gray) and hSDH complexed with
NAD (green). Electron density for NAD is
derived from a Fo  Fc omit map contoured
at 1	 above the mean. Residues whose side
or main chain atoms differ between the two
coordinate sets are shown.
to sorbitol (“reverse” direction, Figure 1A). The equilib- the Km for sorbitol was 1.5 
 0.3 mM (n  5), a value
indistinguishable from that for rat SDH (Oates, 2002). Inrium constant for sheep liver SDH is 3.7 nM (Lindstad
et al., 1992) and, because a proton is part of the mass the “forward” direction, the product fructose exits first,
followed by the rate limiting release of NADH (Lindstadbalance equation together with fructose and NADH, low
pH facilitates fructose reduction to sorbitol, while high et al., 1992). In the presence of 0.5 mM NADH (a subsat-
urating concentration of NADH was used because NADHpH favors sorbitol oxidation to fructose (Lindstad and
McKinley-McKee, 1995). Studies with the enzyme from absorbs strongly at 340 nm, the wavelength used to
monitor the reaction), the Km for fructose is 270 
 63sheep liver have demonstrated that the kinetic mecha-
nism is compulsory ordered bi-bi with the coenzyme mM (n  3). It should be noted that the measured Km
for fructose can be misleading, since only 0.8% of thebinding first and leaving last (Lindstad et al., 1992). To
confirm that all four coenzyme binding and active sites fructose is present in the straight chain form, the likely
substrate form (Maret, 1996). Adjusting the measured(Johansson et al., 2001) were functional in our recombi-
nant human SDH tetramer, binding studies using 14C- Km by this factor gives a corrected Km of 2.2 mM, close
to the 1.5 mM Km measured for sorbitol. Consistent withNAD and 3H-sorbitol were performed. These studies
showed a ratio of one substrate binding site and one the observations of Maret and Auld (1988), we did not
find evidence of substrate inhibition with the humancoenzyme binding site per 38,000 daltons of human
SDH, consistent with 4 molecules of each bound per enzyme.
tetramer (Figure 3A). This provides the first direct evi-
dence in the literature of 1:1 binding stoichiometry of Zn Ligands in hSDH
In the crystal structure of hSDH alone, each catalyticNAD and sorbitol for hSDH monomers. The data also
demonstrate that ligand binding is compulsory ordered, site is marked by the presence of a zinc atom. Each
zinc atom is coordinated by interactions with Cys44,with sorbitol binding dependent on the presence of
NAD, consistent with previous kinetic data on sheep His69, Glu70, and a water molecule (W1952, Figure 3B,
Table 2), but the angles vary from 96 to 120 and areSDH (Lindstad et al., 1992).
We also determined the Michaelis constants of sev- therefore not strictly tetrahedral. In contrast to sugges-
tions from mutagenesis data (Karlsson and Hoog, 1993)eral key substrates and coenzymes for hSDH. The hu-
man enzyme exhibits equal apparent affinities (Km) for and by the 3.0 A˚ structure of rat SDH (Johansson et al.,
2001), the nearby Glu155 is not a direct ligand to theNAD and NADH: 225 
 12 M (n  3) and 210 
 61
M (n 3), respectively. In the presence of 1 mM NAD, zinc atom. Instead, Glu155 is linked to the zinc atom
Structure
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Table 2. Zinc Ligands in Each Structure
Native NAD SeSDH/NADH/CP-166,572
Cys44:S 2.4 Cys44:S 2.5 Cys44:S 2.5
His69:N2 2.2 His69:N2 2.1 His69:N2 2.1
Glu70:O2 2.3 Glu70:O2 2.2 Glu70:O2 3.9
WAT 1952* 2.3 WAT 1862* 2.2 WAT 1064* 2.1
- - CP: N1 2.1
- - CP: O30 2.4
Distances between the atom and the catalytic zinc atom are given in angstroms. Residues within 2.5 A˚ are presumed to be coordinated
directly to the zinc atom. Residues too far to coordinate directly to the zinc atom are in italics. Waters marked with an asterisk are structurally
equivalent.
through the aforementioned water molecule and thus about C to neutralize one of the phosphate oxygens
on NAD. In addition, the backbone atoms of Ile183belongs to the second coordination sphere. The struc-
ture of whitefly NADP(H) ketose reductase shows a very and the carbonyl of Cys249 move to expand the NAD
binding pocket. Comparison of the two structuressimilar coordination of the catalytic zinc with Cys41,
His66, Glu67, and a water molecule linked through shows there are no changes in the residues coordinating
the zinc atom.Glu152 (Banfield et al., 2001). It is possible that, like
Glu68 in ADH, Glu155 may transiently coordinate directly The sequence and structural basis for the selection
of NAD over NADP in dehydrogenases has been de-to the zinc atom to permit release of the product during
catalysis, as proposed from a computational analysis scribed (Baker et al., 1992), and hSDH fits the known
pattern. The primary determinant of NAD dependency(Ryde, 1995).
is the presence of an aspartic acid (in hSDH, Asp203),
which forms hydrogen bonds to the 2 and 3 hydroxylsChanges in hSDH on Binding NAD
of the NAD ribose and occupies the space that wouldThe coenzyme fits neatly into a surface crevice formed
be occupied by the phosphate attached to the 2 hy-by loops emanating from the six  strands forming the
droxyl in NADP. Dehydrogenases that use NADP havecore of the coenzyme binding domain. The conformation
an alanine at this position, which is small enough toof NAD may be compared to the conformation of NADH
leave room for the phosphate. Whitefly ketose reductasebound to mammalian ADH (2OHX.pdb) in the absence
uses NADP as its cofactor and has the requisite alanineof a binary complex of ADH with NAD. Both coenzymes
(residue 199) instead of aspartic acid. Although theadopt nearly identical extended conformations with the
structure lacks coenzyme, a phosphate molecule fromribose in the 2endo puckering conformation and the
the crystallization buffer was found adjacent to alaninenicotinamide ring anti to the ribose (Figure 3C).
199 (Banfield et al., 2001). Superposition of the whiteflyIn the ordered reaction mechanism, NAD binds first
ketose reductase coordinates with those of the SDH/(Figure 3A), and there are small but significant changes
NAD structure shows that this phosphate lies withinin the conformation of a handful of residues to accom-
covalent bonding distance of the 2OH of the ribose ofmodate its bulk (Figure 3C). In contrast, liver alcohol
NAD, exactly where it should be, if NADP were bound.dehydrogenase undergoes a significant domain re-
arrangement on binding its cofactor (Eklund and Bran-
den, 1979). The domain orientation of hSDH is closest hSDH Inhibitor CP-166,572
There is only one class of demonstrated in vivo active(rmsd of 1.3 A˚ for 345 C carbons) to that of the whitefly
NADP(H)-dependent ketose reductase (Banfield et al., sorbitol dehydrogenase inhibitors, the piperazine pyrim-
idines, discovered at Hoechst (Geissen et al., 1992). (A2001), which lacks coenzyme and differs in complicated
ways from both apo ADH (rmsd of 1.8 A˚ for 301 C second class, consisting of dithiothreitol and other metal
chelating thiols, are also potent in vitro inhibitors bycarbons; 8ADH.pdb) and the ADH/NADH complex (rmsd
of 1.9 A˚ for 270 C carbons; 2OHX.pdb). Both the NAD virtue of their interactions with the catalytic zinc [Lind-
stad and McKinley-McKee, 1996].) SDI-157 was initiallyand NADH/SDI complexes were determined from co-
crystals rather than by soaking ligands into an existing described as a sorbitol-raising compound of unknown
mechanism, but was soon found by Geissen (Geissencrystal lattice, suggesting that the domain orientations
in the crystal are biologically relevant. However, it is et al., 1994) and others (Oates et al., 1994) to be a pro-
drug that gave rise to an active SDI, CP-166,572, alsopossible that an alternative domain rearrangement, like
that seen in ADH on binding NADH, occurs in solution called SDI-158 or WAY 135,706 (Cameron et al., 1997)
(Figure 1B). SDI-157 and CP-166,572 provide a dramaticbut is not compatible with the crystal lattice shared
by all three structures or does not occur at the pH of example of the pharmacological power of a small chemi-
cal change: in vivo hydroxylation of the methyl group ofcrystallization (6.2).
Comparing the coordinates of SDH with and without the pyrimidine ring of SDI-157 results in CP-166,572 and
a 1800-fold drop in the IC50 to 0.25 M (Geissen et al.,NAD, the side chains of Arg208, Leu274, and Val296
move to relieve steric clashes with different parts of the 1994). The Ki of CP-166,572 for human SDH is 154 
 22
nM (mean 
 standard deviation, n  3, unpublishedNAD molecule. Of these, the most dramatic change is
the movement of the side chain of Arg208, which breaks data). CP-166,572 is the prototype of this class and is
selective for SDH against other dehydrogenase en-an electrostatic interaction with Asp203 and flips 180
Structure of Human Sorbitol Dehydrogenase
1077
zymes (Geissen et al., 1994), including lactate, alcohol, is engaged in other interactions. Potential hydrogen
bonds could be formed between the oxygen atom andfructose, and glyceraldehyde-3-phosphate dehydroge-
nase, even at concentrations up to 50 M (Oates et His69:N2 (3.0 A˚) or Glu155:O2 (2.4 A˚). Based on the
distance and because His69 is a zinc ligand, Glu155 isal., 1994). We observed that inhibition of hSDH by CP-
166,572 was uncompetitive with respect to NAD, sorbi- likely the hydrogen bond acceptor. With the hydrogen
shared by another atom, the lone pair of electrons ontol, or NADH (Figures 4A– 4C). Inhibition of sheep SDH
by CP-166,572 with respect to fructose has been re- the oxygen is more available for interaction with the zinc
atom.ported to be competitive (Geissen et al., 1994) or mixed
noncompetitive (Lindstad and McKinley-McKee, 1997). In addition to coordinating the zinc, the inhibitor is
stabilized in the catalytic site by numerous hydrophobicWe observed both patterns (Figures 4D and 4E) and
noted that the discrepancy appears to be a function of interactions (Figure 5C). Important stacking interactions
with ideal distances between 3.6 and 4.3 A˚ are achievedthe NADH concentration used, with 500 M NADH (a
concentration above the Km) giving the competitive pat- between the pyrimidine ring of CP-166,572 and the nico-
tinamide ring of NADH. The presence of this hydropho-tern (Figure 4D) and 50 M NADH (less than the Km)
exhibiting a mixed noncompetitive pattern (Figure 4E). bic interaction suggests a reduced affinity of the enzyme
for the inhibitor in the absence of the NADH coenzyme,At 500 M NADH, CP-166,572 also inhibited sheep SDH
competitively with respect to fructose (Figure 4F). Thus, as well as a relatively reduced affinity in the presence
of the charged NAD form of the bound coenzyme. Theunder these conditions, CP-166,572 binds to the
SDH·NADH complex in a manner competitive with fruc- inhibitor is also surrounded by hydrophobic residues on
both sides, which pack closely against it (Tyr50, Ile56,tose in both human and sheep SDH.
The crystal structure of hSDH/NADH/CP-166,572 Phe59, Phe118, Thr121, Leu274, Phe297, and the ali-
phatic part of Arg298). This finding accounts for theshows that CP-166,572 is positioned such that the py-
rimidine ring makes contacts with both the zinc atom remarkable potency of analogs in which the sulfamoyl
group is replaced by planar rings substituted with hy-and NADH, while the piperazine ring and its substituents
extend out toward the surface of the protein (Figures drophobic groups, such as methyl (Mylari et al., 2002).
Aside from the interaction made with the oxygen O305A and 5B). CP-166,572 inhibits substrate binding by
chelating the catalytic zinc atom through strong interac- described above, no other direct hydrogen bonds are
formed between the inhibitor and the protein. One po-tions with both the N1 nitrogen and the O30 oxygen of
the hydroxymethyl. The pyrimidine ring of CP-166,572 tential water-mediated hydrogen bond is formed be-
tween the pyrimidine nitrogen N3 and the guanididiumstacks over the nicotinamide ring of NADH, forming a
tight hydrophobic contact. The inhibitor CP-166,572 group of Arg298. Water molecules are recruited from
those occupying the catalytic site to satisfy the hydro-binds more tightly than either sorbitol or fructose (sub-
micromolar and low millimolar Km’s, respectively) be- gen bonding potential of inhibitor atoms, which are too
far to interact with protein residues. For example, bothcause the inhibitor pyrimidine ring stacks optimally with
NADH while simultaneously presenting O30 and N1 at oxygens of the sulfate group form hydrogen bonds to
water molecules and are accessible to bulk solvent.a fixed distance for coordination to the catalytic zinc.
Although NAD does not alter the constellation of This structure refines previous structural proposals
based on models of ADH (Lindstad and McKinley-amino acid residues coordinating the catalytic zinc, the
inhibitor CP-166,572 does. Glu70 is replaced by two McKee, 1997; Darmanin and El-Kabbani, 2000). In the
first, a hydrogen bond between the hydroxyl group ofligands from the inhibitor, making a total of five coordina-
tion sites (with angles ranging from 74 to 112), rather CP-166,572 and either Glu154 (Glu155 in hSDH) or
Lys293 (Lys298 in hSDH) was suggested, with the N3than the four found in the absence of CP-166,572. Both
the nitrogen N1 of the pyrimidine ring and oxygen O30 of nitrogen of CP-166,572 coordinated to the catalytic zinc
(Lindstad and McKinley-McKee, 1997). However, as in-the hydroxymethyl group of CP-166,572 displace water
molecules to chelate the zinc atom as previously de- dicated earlier, SAR obtained from other pyrimidine ste-
reoisomers of CP-166,572 suggested that the N1 ratherduced from structure-activity relationships (SAR) of iso-
meric pyrimidines (Mylari et al., 2001). Displaced from than N3 served as a ligand to the zinc (Mylari et al.,
2001). The second proposal, based on a model of humanthe zinc atom, Glu70 forms a hydrogen bond to a water
molecule (W1064, the same one that forms a hydrogen SDH derived from structures of alcohol dehydroge-
bond to Glu155 in the NADcomplex). After superimpos- nases, is incorrect, in part because the side chain posi-
ing the coordinates of the SDH/NAD structure onto tions differ significantly from the crystal structure of
the SDH/NADH/CP-166,572, the zinc atom is displaced hSDH and the observed stacking interaction between
2.3 A˚ toward the inhibitor in the CP-166,572 complex. CP-166,572 and the nicotinamide was not predicted
There are also significant changes in the main chain (Darmanin and El-Kabbani, 2000).
and side chain atoms of residues 42–46, most notably
rotation of the side chain of Cys44 to maintain the opti-
Model of Fructose Bound to hSDHmal distance between S and the zinc atom in each
Our kinetic analysis revealed that fructose but not sorbi-structure.
tol competes with CP-166,572 (Figures 4D and 4F; Geis-The strength of the link between the zinc atom and
sen et al., 1994), suggesting that the inhibitor and sub-the oxygen of the hydroxymethyl moiety of CP-166,572
strate binding sites overlap, at least in part (Figure 6).depends on the ability of the oxygen to donate its lone
Like aldose reductase, which acts on the open chainpair of electrons. The availability of these electrons de-
pends on the extent to which their attendant hydrogen form of glucose (Imagaki et al., 1982), SDH likely utilizes
Structure
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Figure 4. Inhibition of hSDH by CP-166,572
Experimental details as described in Experimental Procedures.
(A) Uncompetitive inhibition of hSDH by CP-166,572 with respect to NAD. Forward direction, human SDH.
(B) Uncompetitive inhibition of hSDH by CP-166,572 with respect to sorbitol. Forward direction, human SDH.
(C) Uncompetitive inhibition of hSDH by CP-166,572 with respect to NADH. Reverse direction, human SDH.
(D) Competitive inhibition of hSDH by CP-166,572 with respect to fructose. Reverse direction, human SDH (500 M NADH).
(E) Mixed noncompetitive inhibition of hSDH by CP-166,572 with respect to fructose. Reverse direction, human SDH (50 M NADH).
(F) Competitive inhibition of hSDH by CP-166,572 with respect to fructose for sheep SDH. Reverse direction, sheep SDH (500 M NADH).
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Figure 5. Binding Site of Inhibitor CP-
166,572
(A) Electron density for the inhibitor. Derived
from a 2Fo  Fc omit map contoured at 1	
above the mean.
(B) CP-166,572 interacts with both Zn and
NADH. Stereo image showing the simultane-
ous interaction between the inhibitor and the
catalytic zinc as well as the nicotinamide ring
of NADH. All other ligands to zinc are shown.
(C) Binding site of CP-166,572. Stereo image
showing importance of hydrophobic contacts
in binding inhibitor. All residues (gray carbon
atoms) within van der Waals distance to CP-
166,572 (green carbon atoms) are shown.
Only a single direct hydrogen bond is formed
to the enzyme (to Glu155); all other hydrogen
bonds are formed to water molecules (red
spheres).
the straight chain keto form of fructose for reduction to such that both the C1 hydroxyl and C2 carbonyl oxygens
were in direct coordination with the zinc atom, overlap-sorbitol at the time of hydride delivery from NADH
(Maret, 1996). The presumed driving force for this reduc- ping with the O30 hydroxyl and the N1 nitrogen, respec-
tively, of the inhibitor. The carbons of fructose weretion comes from zinc polarizing the C2 hydroxyl, as has
been suggested for other zinc-mediated reductions. In roughly aligned with the pyrimidine and piperazine rings
of the inhibitor to optimize hydrophobic interactions.the absence of crystallographic data for substrate bind-
ing to any sorbitol dehydrogenase, we developed a The coordinates of CP-166,572 were replaced with
those of fructose, and the complex of SDH/ NADH/fruc-model of fructose binding using the binding mode we
observed for CP-166,572, i.e., with the zinc penta-coor- tose was subjected to minimization in the absence of
X-ray data using CNS (Brunger et al., 1998).dinated. Zinc is usually coordinated to 4 or 5 ligands
in the active sites of enzymes, including bound water After minimization, the O1 and O2 oxygens of fruc-
tose are directly coordinated to the catalytic zinc atom.molecules, inhibitors, or intermediates (Lipscomb and
Strater, 1996). O1 also potentially makes two hydrogen bonds to
Glu155:O2 and/or His69:N2. In this position, the C2We manually positioned a linear fructose molecule
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Figure 6. Model of Fructose Binding and Catalyic Mechanism
(A) Stereo image of proposed binding site for fructose (green carbon atoms) superimposed on bound CP-166,572 (in light gray). In this position,
the C1 and C2 oxygens of fructose are directly coordinated to zinc, and the C2 carbon is correctly aligned with the C4 atom of NADH, poised
for the reverse reaction.
(B) Model for reduction of sorbitol to fructose, followed by cyclization of fructose. (1) A schematic of the zinc ligands derived from the native
crystal structure. (2) Sorbitol binds after NAD, resulting in the zinc atom being penta-coordinated; the arrows depict the electron movement
entailed in oxidation of the C2 carbon to form fructose with hydride transfer to NAD. (3) Reverse flow of electrons from NADH to reduce
fructose to sorbitol. (3A) Cyclization to the furanose form of fructose. (4) Release of product with zinc coordination returning to the tetra-
coordinated state.
carbon of fructose is within van der Waals distance of arginine side chains stack under adenine rings in DNA/
protein complexes.the reactive carbon of NADH and carbons C3, C4, and
C5 are packed against the nicotinamide ring. We pre-
sume that the remaining hydroxyls of fructose will be Proposed Mechanism
To summarize, we propose the following structuralsolvated by the numerous water molecules in the cata-
lytic site. In addition, Arg298 is likely to alter its side changes as catalysis occurs in the forward direction
(Figure 6B). In the absence of any ligand, the zinc atomchain conformation to form a hydrogen bond to the O3
or O6 oxygen. An important component of the binding is tetra-coordinated by three protein side chains (Cys44,
His69, Glu70) and one water molecule (Figure 6B (1)).energy comes from hydrophobic interactions between
fructose and NADH. The C2 to C5 carbons of the fruc- The required cofactor, NAD, binds first, and small but
significant movements in main chain and side chaintose stack against the planar hydrophobic nicotinamide
ring, reminiscent of the way the aliphatic portions of atoms occur to accommodate it, followed by the binding
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of sorbitol. Sorbitol binds with both its C1 and C2 oyxgen the neutrally charged pyrimidine ring of the inhibitor
[Figures 5C and 6A]); hence, CP-166,572 and fructoseatoms coordinated to zinc with the simultaneous release
of Glu70, making the zinc pentavalent (Figure 6B (2)). would compete with one another. In contrast, the posi-
tively charged nicotinamide ring of NAD (which existsThe backbone carbons C3–C5 of sorbitol overlap with the
linear fructose model herein proposed (Figure 6A). The only in the presence of sorbitol) may better accommo-
date the pyrimidine ring of CP-166,572 in the unchargedcarbon backbone of sorbitol stacks in part against
the nicotinamide ring, an interaction that is consistent state. Thus, CP-166,572 might compete effectively with
substrate only when NADH, but not NAD, is bound.with the observed ordered mechanism.
Oxidation of sorbitol to fructose in the enzyme-sub- An alternative possibility is that CP-166,572 competes
(only) with the furanose form of fructose on the enzymestrate complex now formed requires a base to remove
the hydrogen from the C2 oxygen of sorbitol coordinated surface and not with the linear form of this ketose (Figure
6B (4)). Further studies will be necessary to resolve theseto zinc. One candidate for this role is water molecule
W1952, which forms a hydrogen bond to Glu155 in the and related questions, such as the actual coordination
state of zinc in the presence of sorbitol and fructoseapo enzyme and to both Glu155 and Glu70 in the com-
plexes with the inhibitor and our model for fructose. This substrates.
In summary, we have purified, crystallized, and deter-water molecule is proposed to function as a general
base, which abstracts the proton of the zinc-coordi- mined the crystal structures of human SDH in its native
state, as a complex with NAD and as a ternary complexnated C2 hydroxyl, setting up the cascade of events to
deliver the hydride at C2 to NAD with concomitant with NADH and a prototype inhibitor, CP-166,572. These
structures provide a view of the reaction pathway duringcharge neutralization of NAD to NADH and oxidation
of the C2 hydroxyl to the keto group of fructose (arrows, catalysis and a firm foundation for understanding the
mechanism of action of reversible inhibitors of SDH.Figure 6B (2)). The reverse flow of electrons from NADH
to reduce fructose to sorbitol is depicted in Figure 6B
Experimental Procedures(3, arrows). In the forward direction (Figure 6B (4, via
3A)), since fructose blocks the exit of NADH from the
Cloning and Expression of Human SDHprotein, fructose must be released first, followed by the
A pET vector system (Novagen) was used for expression of human
release of NADH and the subsequent return of residues SDH. The SDH gene previously identified in a human liver cDNA
around the catalytic zinc to their original tetra-coordi- library (Iwata et al., 1995) was kindly provided by Dr. Jan-Olov Ho¨o¨g
nated configuration. (Karolinska Institute, Stockholm, Sweden) and was used as a tem-
plate for polymerase chain reaction (PCR) amplification. Two prim-A key issue is whether the fructose and sorbitol sub-
ers were designed to amplify the DNA fragment coding for hSDH.strates bind to the enzyme in precisely the same way
The 5 primer (5-GGAATTCCATATGGCGGCGGCGGCCAAGCCC-3)CP-166,572 does. In the present case, speculations on
introduced a unique NdeI site, while the 3 primer (5-GGCCGCT
this point are subject to the caveat that the enzyme CGAGCTATTAGGGATTCTGGTCACTGGG-3) introduced a unique
crystals were grown at pH 6.2 and the results may differ XhoI site preceded by TAA and TAG stop codons. PCR amplification
from what occurs at neutral pH, the conditions under was carried out under standard conditions using Vent polymerase
and the human liver cDNA library as a template. The PCR-amplifiedwhich the enzyme kinetic studies were performed. In
product was digested with NdeI and XhoI, gel purified, and ligatedthe absence of definitive data that will come only from
into pET23a (Novagen) and transformed into E. coli DH5 cells.the solution of additional crystal structures, we can nev-
Positive clones were selected and plasmids subjected to restriction
ertheless note that in the presence of 500 M NADH, digestion and PCR analysis to confirm the presence of the insert.
fructose competes with CP-166,572 (Figures 4D and The DNA sequence of the 1071 base pair insert in pET23a was
4F); this implies, but does not prove, that the latter two confirmed (identical to the human SDH sequence GenBank acces-
sion number U07361) on both strands.ligands have one or more binding sites on the enzyme
surface that overlap. On the other hand, in the presence
Cell Growth and Initial Expressionof the inhibitor, the catalytic zinc is coordinated by only
E. coli BL21(DE3)/pET23a,1/3-hSDH-MCB3 was cultured in a mediatwo protein ligands plus a water molecule (Figure 5B).
comprising 10 g/l dextrose, 6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l NH4Cl,This coordination state is unusual; in all other zinc en- 0.5 g/l NaCl, 5 g/l Casamino Acids, 0.5 g/l MgSO4·7H2O, 10 mg/l
zymes, the catalytic zinc is coordinated by three amino CaCl2, 1 mg/l thiamine, 0.5 ml/l P-2000, and 25 mg/l ampicillin·3H2O
acid side chains with either a water molecule or another at 30C until OD at 550 nm reached between 1.0 and 1.5. Then, 1
mM of IPTG was added and temperature reduced to 25C. The pHside chain as the fourth ligand. It is therefore possible
during the IPTG induction phase was controlled above 6.6 usingthat the fructose and sorbitol substrates do not bind like
20% NaOH. The induction phase was allowed to go on for aboutCP-166,572, but instead interact with the zinc through
24 hr to maximize the expression of soluble, active hSDH. The cul-a single coordinating oxygen, e.g., the C2 hydroxyl. It
ture broth was then chilled to 10C, and cells containing soluble,
should be noted that coordination by either a single active hSDH were pelleted by centrifugation.
substrate oxygen or by two substrate oxygens does not
per se explain the occurrence of a competitive inhibition Growth of Selenomethionine-Substituted hSDH
pattern between CP-166,572 and fructose but not be- A glycerol stock of E. coli BL21 (DE3) cells harboring hSDH/pET23a
1/3 was cultured overnight at 37C with shaking at 300 rpm in 2 tween CP-166,572 and sorbitol (Figures 4B and 4D;
YT media (16 g Bacto-Tryptone, 10 g yeast extract, 5 g NaCl, in 1 lGeissen et al., 1994).
water) containing 100 g/ml carbenicillin. Plasmid DNA was pre-One factor which could explain the inhibition pattern
pared from these cells (Qiagen), transformed into B834(DE3) cellsof CP-166,572 is that the neutral nicotinamide ring of
(Novagen), and used for expression in selenomethionine media.
the NADH cofactor may form an important part of the Selenomethionine (SeMet) media contains 10 g/l (NH4)2SO4, 2.16
hydrophobic interactions in the binding site for fructose g/l Na2HPO4, 1.28 g/l KH2PO4, 5 g/l NaCl, 0.4 g/l trisodium citrate
(Sigma C-7254), 0.2 g/l MgSO4, 2 mg/l thiamine, 10 g/l glycerol, 0.1as it does for CP-166,572 (in the case of CP-166,572 via
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g/l carbenicillin, 40 mg/l of all L-amino acids except methionine, 8 methionines substituted with selenomethionine. The selenomethi-
onine-substituted protein was assayed using the same method as100 mg/l D, L-selenomethionine (Bachem, Cat#: GSEL20), 10 mg/l
CaCl2, 4 mg/l H3BO3, 1.71 mg/l MnSO4, 2 mg/l ZnSO4, 0.373 mg/l wild-type protein and the activity was the same within error.
CuSO4, 0.4 mg/l CoCl2, 0.2 mg/l Na2MoO4, adjusted to pH 7.0. A
500 ml culture of the hSDH clone in B834(DE3) in SeMet media was Determination of NAD and Sorbitol Binding to SDH
inoculated from an overnight culture grown at 30C in the same Twenty-five microliters 5 mM [14C]-NAD 
 25l 50 mM [3H]-sorbitol
media and grown to an OD600 of 0.5 to 1.0, at which point the cells (New England Nuclear, Boston, MA) and 25 l 100 mM potassium
were induced with IPTG (1.0 mM final concentration). After growth phosphate buffer (pH 7.0) were added at 4C to 200 l 10 nM hSDH
for 24 hr at room temperature, the cells were harvested by centrifu- (assuming 38,072 daltons/monomer), mixed, added to Microcon mi-
gation and stored at 80C. croseparators (Amicon, Beverly, MA, 20 kDa cut-off), and centri-
fuged at 100  g for 2 min at 4C. Two 50 l aliquots of eluate were
counted in a liquid scintillation counter (Wallac, Turku, Finland).Purification of Recombinant Human Sorbitol
Dehydrogenase from E. coli Cells Each microseparator was inverted and 150 l potassium phosphate
buffer was added. After centrifugation as before, two 50 l aliquotsThe method was modified from a published procedure (Maret and
Auld, 1988). E. coli (40–50 g) BL21DE3 pET 23a/hSDH cells were of this second eluate were counted to determine enzyme bound
NAD and/or sorbitol. 14C-NAD specific activity corrected for slightresuspended with two volumes of lysis buffer (20 mM HEPES/NaOH
[pH 8], 5 M ZnCl2, 2 mM DTT, 1 mM PMSF, 20 g/ml aprotinin). (2% per year) autolytic degradation as per manufacturer’s (NEN)
data. Overall recoveries were 85%–110%.Two volumes of lysis buffer containing 2 mg/ml lysozyme were
added, and the mixture was stirred on ice for 60 min followed by
sonication. The sonicated cells were centrifuged at 12,000 rpm for 10 Km Values of Human SDH
min at 4C, the supernatant was decanted, and the pellet discarded. Human SDH was diluted to a stock solution of 5 nM with 100 mM
Ammonium sulfate was added to the supernatant to a final con- potassium phosphate buffer (pH 7.1) for “forward” reaction studies
centration of 40%, and the solution was placed on ice for 30 min (sorbitol oxidation to fructose) and to 2.5 nM for “reverse” reaction
and then centrifuged at 12,000 rpm for 10 min. The supernatant was studies (fructose reduction to sorbitol). Varying concentrations of
removed and ammonium sulfate was added to a final saturation of substrates and coenzymes, all purchased from Sigma (St. Louis,
60%, incubated on ice for 30 min, and then centrifuged as before. MO), were prepared in deionized water from stock solutions of 500
The 40%–60% ammonium sulfate pellet was dissolved with 100 mM sorbitol, 10 mM NAD (sodium salt), 5 mM NADH, and 4 M
ml 20 mM HEPES/NaOH [pH 8.0], 5 M ZnCl2, 2 mM DTT, 1 mM fructose. Two hundred microliters SDH were added to each well of
PMSF, and 1 g/ml each of aprotinin, pepstatin, and leupeptin and a 96-well microtiter plate, and 25 l 10 mM NAD or 5 mM NADH
dialyzed overnight at 4C against the same buffer. was added as appropriate followed by a 10 min incubation at room
temperature. The reaction was initiated by the addition of 25 l
of varying concentrations of sorbitol (to NAD/SDH mixtures) orGreen A Chromatography
A Green A dye column (XK-50, Pharmacia) was equilibrated with fructose (to NADH/SDH mixtures) solutions. The rate of reaction
was measured by monitoring the absorbance at 340 nm for 3 min800 ml Buffer A (20 mM HEPES/NaOH [pH 8], 5 mM ZnCl2, and 2
mM DTT). The 40%–60% ammonium sulfate fraction, containing at room temperature. Data were analyzed via nonlinear (hyperbolic)
regression using GraphPad Prism Software (GraphPad Prism, Inc.,about 50–200 mg is hSDH protein, was loaded onto the column.
The column was eluted with a 0–1 M NaCl gradient in Buffer A. Four San Diego, CA).
minute fractions were collected and assayed for activity. The major
peak of activity, which eluted between 150–300 mM NaCl, was Enzyme Kinetic Inhibition Patterns with CP-166,572
pooled, concentrated to 50 ml in an Amicon cell using a YM-30 Two hundred microliters of 25 nM hSDH in 625 or 62.5 M NADH
membrane, and dialyzed overnight at 4C against Buffer A. in 100 mM potassium phosphate buffer (pH 7.0) was placed in each
well of a 96-well plate. Twenty-five microliters of aqueous stock
solutions of SDH inhibitor 2-hydroxylmethyl-4-(4-N,N-dimethylami-Mono S Chromatography
The dialyzed material was loaded onto a Mono S column (Pharmacia) nosulfonyl-1-piperazino) pyrimidine (CP-166,572 or SDI 158; Geis-
sen et al., 1994; Department of Medicinal Chemistry, Pfizer Globalequilibrated in Buffer A at 4C and eluted using a 0–150 mM NaCl
gradient. Material prepared by this was at least 95% pure by silver- Research and Development, Groton, CT) were added to give final
concentrations of 100–300 nM, and the wells were allowed to prein-stained SDS-PAGE and had a specific activity of 8–10 U in the assay
described below. Electrospray mass spectrometry indicated a major cubate for 10 min at room temperature. The reaction was initiated
by the addition of 25 l of one of several aqueous stocks of eitherpeak centered at 38178 and a lesser peak centered at 38112 mass
units (expected mass 38202). N-terminal sequence analysis indi- fructose, sorbitol, or NAD. The rate of reaction was measured by
monitoring the absorbance at 340 nm at room temperature over 3cated AAAAKPNNLSLV with 29% of the protein missing the first
alanine. min on a SLT LabInstruments 96-well plate reader (Salzburg,
Austria).
Activity Assay
An aliquot of each fraction (with an average concentration of 0.1–0.2 Km Values for NAD and NADH
Two hundred microliters SDH were added to each well of a 96-mg/ml) was diluted 20-fold in a solution containing 20 mM HEPES/
NaOH (pH 8) and 200 mM NaCl. The reaction was initiated by adding well microtiter plate, and 25 l of varying concentrations of NAD
(forward reaction) or NADH (reverse reaction) were added and the5–10 l of this diluted sample to a reaction mixture consisting of 1
mM NAD, 50 mM sorbitol, 0.1 M glycine/NaOH (pH 10), at 25C. solutions incubated for 10 min at room temperature. The reaction
was initiated by the addition of 25 l 500 mM sorbitol (to NADThe absorbance of the sample was monitored at 340 nm. The spe-
cific activity of the enzyme is defined as micromoles of NADH pro- mixtures) or 25 l 4 M fructose (to NADH mixtures). The rate of
reaction was measured by monitoring the absorbance at 340 andduced per minute per milligram at 25C and was calculated as fol-
lows: mol/min/mg [(OD340)(1000 mM/mM)(0.001 l)]/[(6.22)(mM/l)1 data analyzed as described above.
(min)(mg SDH in assay)]. The specific activity of hSDH in these
studies was determined to be 11.6 
 0.9 U/mg. Crystallization of hSDH Protein
Both the wild-type and selenomethionine-substituted proteins were
concentrated to 2.0 mg/ml in a 20 mM HEPES/NaOH (pH 7.8) con-Purification of Selenomethionine-Substituted hSDH
Selenomethionine-substituted hDSH was purified and assayed in taining 100 mM NaCl, 2 mM DTT, 0.1 mM NADH, and 0.2 mM of CP-
166,572. Crystals were grown in hanging drops by vapor diffusion atthe same way as the wild-type protein. Electrospray mass spectrom-
etry indicated a major peak centered at 38565 and a lesser peak 22C. The well solution consisted of 150 mM NH4OAc, 100 mM
NaCitrate (pH 6.15), 30% PEG-4000, and 2.5 mM DTT. Six microliterscentered at 38492 mass units (expected mass for 7 selenomethio-
nines and 1 Zn2 is 38534). These are 11 and 9 of the predicted of protein solution were mixed with 3 l of well solution. Under these
conditions, large (0.3  1.0 mm) crystals appeared in 4 to 8 days.masses of 38554 (des Met) and 38483 (des Met Ala) forms with all
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Crystals of SDH without NADH or inhibitor were prepared in the amino acid sequence could be deduced directly from the electron
density. Analysis of the selenium site locations and the electronsame way, except the well solution contained 28% PEG-4000 and
10 mM ZnCl2. Crystals of SDH with NAD were prepared in the same density map indicated that residue 185 was in fact a selenomethio-
nine, rather than a glutamic acid. We used the C trace of a theoreti-way except the protein solution contained 0.2 mM NAD and the
well solution contained 26.5% PEG-4000 and 10 mM ZnCl2. cal model of sheep liver sorbitol dehydrogenase (PDB entry 1SDG,
based on horse liver alcohol dehydrogenase; Eklund et al., 1985)
as a starting point for model building of one monomer. NAD, CP-Stabilization of the Crystals prior to Freezing
166,572, the catalytic zinc, and residues 4–356 of each monomerPrior to data measurement, crystals were stabilized by stepwise
were unambiguously positioned in the map using the program Otransfer into a cryostabilization solution (30% PEG-4000, 37.5 mM
(Jones et al., 1991).NH4OAc, 50 mM NaCitrate [pH 6.15], 8.75% glycerol, 0.07 mM NADH,
and 0.14 mM CP-166,572), after which they were frozen either di-
Refinementrectly in a liquid nitrogen gas stream or in liquid propane.
The structure was refined using the MLHL maximum likelihood in
CNS (Adams et al., 1999). Crossvalidation used 5% of the reflectionsData Measurement and Reduction
selected prior to the start of refinement. One molecule was manuallyFor phasing, the data were measured from a single crystal at 100 K
refit in O (Jones et al., 1991), and the other three were regeneratedat beamline 5.0.2 at the Advanced Light Source at the Lawrence
by application of noncrystallographic symmetry. Standard CNS pro-Berkeley Laboratory (Berkeley, CA). The X-ray absorption spectrum
tocols of rigid body refinement, overall B factor refinement of eacharound the K edge of the anomalously scattering selenomethionine
monomer, grouped B factor refinement of main chain and side chainatoms was measured using a simple X-ray detector mounted at
atoms, minimization, torsional dynamics, individual B factor refine-right angles to the X-ray beam and in the horizontal plane to capture
ment, and automatic water picking were used. Prior to torsionalfluorescence as an indirect measure of absorption. The peak wave-
dynamics, values for f and f″ were refined for the selenium and zinclength was identified as 0.97949 A˚ from the fluorescence scan. A
atoms. These anomalous scattering contributions were included incomplete data set to a maximum resolution of 1.9 A˚ was measured
structure factor calculations in all subsequent steps. The structureusing a ADSC Quantum 4 detector. For each wavelength, a 90
was refined using all data at the peak wavelength between 99.0 andwedge of data was measured, after which phi was rotated by 180
1.9 A˚ and resulted in a final free R value of 0.183 and R value ofand the same wedge of data remeasured to collect the Bijvoet pairs.
0.211 (Table 1). The starting models for the native enzyme and SDH/The data were reduced and scaled using Denzo and Scalepack
NAD complex consisted of the coordinates for SDH/NADH/CP-(Otwinowski and Minor, 1997), keeping the Bijvoet pairs separate.
166,572 complex with ligands removed. Refinement of the nativeData sets of the complexes with NAD and NADH/CP-166,572 were
enzyme and SDH/NAD complex used the standard methods de-measured from a single crystals at 100 K at beamline X12C at the
scribed above and resulted in final free R values of 0.233 and 0.222National Synchrotron Light Source at the Brookhaven National Lab-
and R values of 0.200 and 0.195, respectively (Table 1).oratory (Upton, NY), using the Brandeis B4 or B1.2 detectors (Phillips
et al., 2000).
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